297 related articles for article (PubMed ID: 17346211)
1. Strategies to design inhibitors of Clostridium botulinum neurotoxins.
Cai S; Singh BR
Infect Disord Drug Targets; 2007 Mar; 7(1):47-57. PubMed ID: 17346211
[TBL] [Abstract][Full Text] [Related]
2. Current strategies for designing antidotes against botulinum neurotoxins.
Patel K; Cai S; Singh BR
Expert Opin Drug Discov; 2014 Mar; 9(3):319-33. PubMed ID: 24520991
[TBL] [Abstract][Full Text] [Related]
3. Challenges in searching for therapeutics against Botulinum Neurotoxins.
Pirazzini M; Rossetto O
Expert Opin Drug Discov; 2017 May; 12(5):497-510. PubMed ID: 28271909
[TBL] [Abstract][Full Text] [Related]
4. Natural Compounds and Their Analogues as Potent Antidotes against the Most Poisonous Bacterial Toxin.
Patel KB; Cai S; Adler M; Singh BK; Parmar VS; Singh BR
Appl Environ Microbiol; 2018 Dec; 84(24):. PubMed ID: 30389764
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.
Derman Y; Selby K; Miethe S; Frenzel A; Liu Y; Rasetti-Escargueil C; Avril A; Pelat T; Urbain R; Fontayne A; Thullier P; Sesardic D; Lindström M; Hust M; Korkeala H
Toxins (Basel); 2016 Sep; 8(9):. PubMed ID: 27626446
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening technologies for botulinum neurotoxins.
Bompiani KM; Dickerson TJ
Curr Top Med Chem; 2014; 14(18):2062-80. PubMed ID: 25335886
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
8. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
9. Botulinum neurotoxins and botulism: a novel therapeutic approach.
Thanongsaksrikul J; Chaicumpa W
Toxins (Basel); 2011 May; 3(5):469-88. PubMed ID: 22069720
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of equine botulism heptavalent antitoxin against all seven botulinum neurotoxins in symptomatic guinea pigs.
Barker D; Gillum KT; Niemuth NA; Kodihalli S
PLoS One; 2019; 14(9):e0222670. PubMed ID: 31527885
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug discovery for botulinum neurotoxins.
Swaminathan S
Curr Top Microbiol Immunol; 2013; 364():197-218. PubMed ID: 23239355
[TBL] [Abstract][Full Text] [Related]
12. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.
Dickerson TJ; Smith GR; Pelletier JC; Reitz AB
Curr Top Med Chem; 2014; 14(18):2094-102. PubMed ID: 25335884
[TBL] [Abstract][Full Text] [Related]
13. New targets in the search for preventive and therapeutic agents for botulism.
Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
[TBL] [Abstract][Full Text] [Related]
14. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling.
Kumar G; Kumaran D; Ahmed SA; Swaminathan S
Acta Crystallogr D Biol Crystallogr; 2012 May; 68(Pt 5):511-20. PubMed ID: 22525749
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.
Chang TW; Blank M; Janardhanan P; Singh BR; Mello C; Blind M; Cai S
Biochem Biophys Res Commun; 2010 Jun; 396(4):854-60. PubMed ID: 20452328
[TBL] [Abstract][Full Text] [Related]
16. Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins.
Capková K; Salzameda NT; Janda KD
Toxicon; 2009 Oct; 54(5):575-82. PubMed ID: 19327377
[TBL] [Abstract][Full Text] [Related]
17. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.
Kalb SR; Santana WI; Geren IN; Garcia-Rodriguez C; Lou J; Smith TJ; Marks JD; Smith LA; Pirkle JL; Barr JR
BMC Biochem; 2011 Nov; 12():58. PubMed ID: 22085466
[TBL] [Abstract][Full Text] [Related]
18. Small molecule non-peptide inhibitors of botulinum neurotoxin serotype E: Structure-activity relationship and a pharmacophore model.
Kumar G; Agarwal R; Swaminathan S
Bioorg Med Chem; 2016 Sep; 24(18):3978-3985. PubMed ID: 27353886
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model.
Emanuel A; Qiu H; Barker D; Takla T; Gillum K; Neimuth N; Kodihalli S
PLoS One; 2019; 14(1):e0209019. PubMed ID: 30633746
[TBL] [Abstract][Full Text] [Related]
20. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities.
Dembek ZF; Smith LA; Rusnak JM
Disaster Med Public Health Prep; 2007 Nov; 1(2):122-34. PubMed ID: 18388640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
